Work

The SOLARIS protocol: a phase 3, randomized, double-blind, placebo-controlled trial assessing safety and efficacy of TV-44749 in adults with schizophrenia

Year: 2023

Type: article

Source: Neuroscience Applied

DOI: 10.1016/j.nsa.2023.103589

Authors: C.U. Correll, A. Ahn, T. Bar-Nur, A. Merenlender-Wagner, N. Sharon, K.R. Franzenburg, M. Suett, I. Cherniakov, O. Pelleg, E. Harary, A. Elgart

Institutions: Northwell Health, Feinstein Institute for Medical Research, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Zucker Hillside Hospital, Charité – Universitätsmedizin Berlin, Teva Pharmaceuticals (United States), Teva Pharmaceuticals (Israel)

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000

OpenAlex ID: W4390222386

FWCI: 0.408

Cites:

Cited by: 2

Related to: 10